Therapeutics/Diagnostics News

Although CT imaging remains standard of care for determining surgical management needs for small bowel obstruction, clinical features alone performed equally well and with greater accuracy, according to data published in JAMA Network Open.

In the second half of 2023, there were numerous landmark FDA approvals for gastroenterology and hepatology, in particular for the treatment of ulcerative colitis, with four new options squeezing into an already saturated market.

The AGA has published the first comprehensive guideline on the management of pouchitis and other inflammatory pouch disorders among patients with ulcerative colitis who have undergone ileal pouch-anal anastomosis surgery.

Heavy binge drinking and high polygenic risk score were associated with a sixfold higher relative excess risk for alcohol-related cirrhosis, with the presence of diabetes mellitus further increasing the risk, researchers reported.

Among patients with negative fecal immunochemical tests, those with values in the upper range demonstrated higher risk for advanced neoplasia vs. those in the lower range, according to data in Annals of Internal Medicine.

The ColoSense multitarget stool RNA test demonstrated high sensitivity for detection of colorectal cancer and advanced adenoma, notably in individuals aged 45 to 49 years, according to data in JAMA.

A test-and-treat model for hepatitis C virus infection among injection drug users and people experiencing homelessness resulted in high levels of treatment initiation, completion and cure, and may expand care access to marginalized groups.

Laparoscopic pancreaticoduodenectomy had similar short-term outcomes compared with open surgery among patients with pancreatic ductal adenocarcinoma, according to study results published in JAMA Surgery.

Diagnostic test completion for early age-onset colorectal cancer is low among U.S. veterans presenting with iron-deficiency anemia or hematochezia, with women and Black and Hispanic veterans less likely to undergo follow-up testing.

The cost of liquid biopsy for second-line colorectal cancer screening was not cost-effective and would have to be reduced by 66% to increase uptake among the general population, according to data in JAMA Network Open.